Search
Search Results
-
KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth
Anaplastic lymphoma kinase (ALK), which belongs to the insulin receptor tyrosine kinase superfamily, plays an important role in nervous system...
-
Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
IntroductionAnaplastic lymphoma kinase ( ALK ) gene rearrangements, have been identified in approximately 2-7% of patients with lung adenocarcinoma...
-
Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics
Purpose of ReviewAnaplastic thyroid carcinoma is a type of thyroid carcinoma with the most aggressive biological behaviour amongst thyroid cancer....
-
Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Although kinase inhibitors (KI) frequently portray large interpatient variability, a ‘one size fits all’ regimen is still often used. In the...
-
Long-term treatment with ALK inhibitors for postoperative recurrence of ALK-rearranged lung cancer
We encountered a 40-year-old female patient who developed, in chronological order, carcinomatous pleuritis and lymphangitis, multiple lymph node...
-
Efficacy of tyrosine kinase inhibitors in patients with non-small-cell lung cancer with performance status 4: a case series and review of the literature
BackgroundCurrent guidelines for non-small-cell lung cancer (NSCLC) recommend that each tyrosine kinase inhibitor (TKI) is indicated even for driver...
-
A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report
In resected non-small cell lung cancer (NSCLC), ALK rearrangements are associated with worse recurrence-free survival (RFS) than other driver genes....
-
Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects followin
g oral administrationPurposeEnsartinib is a novel, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK) that has promising clinical activity and low...
-
Primary breast lymphoma of childhood: a case report and review of literature
BackgroundPrimary breast lymphoma (PBL) is an extremely rare neoplasm in children; by definition, it manifests in the breast without evidence of...
-
Anaplastic Large Cell Lymphoma with Oral Manifestation: A Series of Four Cases and Literature Review
The aim of this study was to describe the clinicopathological and immunohistochemical features of four cases of anaplastic large cell lymphoma (ALCL)...
-
18F-FDG PET/CT imaging findings in anaplastic large cell lymphoma, a rare subtype of lymphoma
ObjectiveTo investigate the 18 F-FDG PET/CT imaging manifestations for anaplastic large cell lymphoma (ALCL), a rare subtype of T/NK cell lymphoma.
...
-
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained prominence as the most effective pathway-directed anti-cancer...
-
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL
Classical Hodgkin lymphoma (cHL) and anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL) are B and T cell lymphomas...
-
Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?
PurposeAnaplastic lymphoma kinase (ALK) mutations occurs in approximately 3–5% of patients with non-small cell lung cancer (NSCLC). Pleural...
-
ALK-rearranged renal cell carcinoma with TPM3::ALK gene fusion and review of the literature
ALK-rearranged renal cell carcinoma (ALK-RCC) is a very rare novel molecularly defined entity in the recently published fifth edition of the World...
-
Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma
BackgroundAnaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) improve outcomes for non-small-cell lung cancer (NSCLC) patients with ALK ...
-
Personalized medicine: paradigm shift in ALK positive non-small cell lung cancer: a case report
BackgroundSince the identification of multiple therapeutic targets, as is the case of anaplastic lymphoma kinase (ALK) translocation, the paradigm of...
-
The oncogenic fusion landscape in pediatric CNS neoplasms
Pediatric neoplasms in the central nervous system (CNS) are the leading cause of cancer-related deaths in children. Recent developments in molecular...
-
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that phosphorylate tyrosine residues of critical molecules in...
